CHLORDIAZEPOXIDE HYDROCHLORIDE/CLIDINIUM BROMIDE- chlordiazepoxide hydrochloride and clidinium bromide capsule

Land: Vereinigte Staaten

Sprache: Englisch

Quelle: NLM (National Library of Medicine)

Kaufe es jetzt

Gebrauchsinformation Gebrauchsinformation (PIL)
01-04-2019
Fachinformation Fachinformation (SPC)
01-04-2019

Wirkstoff:

CHLORDIAZEPOXIDE HYDROCHLORIDE (UNII: MFM6K1XWDK) (CHLORDIAZEPOXIDE - UNII:6RZ6XEZ3CR), CLIDINIUM BROMIDE (UNII: 91ZQW5JF1Z) (CLIDINIUM - UNII:BO76JF850N)

Verfügbar ab:

A-S Medication Solutions

INN (Internationale Bezeichnung):

CHLORDIAZEPOXIDE HYDROCHLORIDE

Zusammensetzung:

CHLORDIAZEPOXIDE HYDROCHLORIDE 5 mg

Verabreichungsweg:

ORAL

Verschreibungstyp:

PRESCRIPTION DRUG

Anwendungsgebiete:

Chlordiazepoxide Hydrochloride/Clidinium Bromide is indicated to control the emotional and somatic factors in gastrointestinal disorders. Chlordiazepoxide Hydrochloride/Clidinium Bromide may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. Chlordiazepoxide Hydrochloride/Clidinium Bromide is contraindicated in the presence of glaucoma (since the anticholinergic component may produce some degree of mydriasis) and in patients with prostatic hypertrophy and benign bladder neck obstruction. It is contraindicated in patients with known hypersensitivity to chlordiazepoxide hydrochloride and/or clidinium bromide. Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuance of chlordiazepoxide. The more severe withdrawal symptoms have

Produktbesonderheiten:

Product: 50090-0131 NDC: 50090-0131-0 30 CAPSULE in a BOTTLE

Berechtigungsstatus:

unapproved drug other

Gebrauchsinformation

                                AND CLIDINIUM BROMIDE CAPSULE
A-S Medication Solutions
Disclaimer: This drug has not been found by FDA to be safe and
effective, and this labeling has not been
approved by FDA. For further information about unapproved drugs, click
here.
----------
Issued: 02/2017
MEDICATION GUIDE
Chlordiazepoxide Hydrochloride/Clidinium Bromide capsules
What is the most important information I should know about
Chlordiazepoxide Hydrochloride/Clidinium
Bromide Capsules?
•
Do not stop taking Chlordiazepoxide Hydrochloride/Clidinium Bromide
without first talking to
your healthcare provider. Stopping Chlordiazepoxide
Hydrochloride/Clidinium Bromide suddenly
can cause serious side effects.
•
Taking Chlordiazepoxide Hydrochloride/Clidinium Bromide with opioid
medicines, alcohol, or
other central nervous system depressants (including street drugs) can
cause severe drowsiness,
breathing problems (respiratory depression), coma and death.
•
Do not drive, operate heavy machinery, or do other dangerous
activities until you know how
Chlordiazepoxide Hydrochloride/Clidinium Bromide affects you.
•
Do not drink alcohol or take other drugs that may make you sleepy or
dizzy while taking
Chlordiazepoxide Hydrochloride/Clidinium Bromide without first talking
to your healthcare
provider. When taken with alcohol or drugs that cause sleepiness or
dizziness,
Chlordiazepoxide Hydrochloride/Clidinium Bromide may make your
sleepiness or dizziness
much worse.
•
Chlordiazepoxide Hydrochloride/Clidinium Bromide can cause abuse and
dependence.
•
Do not stop taking Chlordiazepoxide Hydrochloride/Clidinium Bromide
all of a sudden.
Stopping Chlordiazepoxide Hydrochloride/Clidinium Bromide suddenly can
cause seizures,
shaking, stomach and muscle cramps, vomiting and sweating.
•
Physical dependence is not the same as drug addiction. Your healthcare
provider can tell you
more about the differences between physical dependence and drug
addiction.
What is Chlordiazepoxide Hydrochloride/Clidinium Bromide?
•
Chlordiazepoxide Hydrochloride/Clidinium Bromid
                                
                                Lesen Sie das vollständige Dokument
                                
                            

Fachinformation

                                CHLORDIAZEPOXIDE HYDROCHLORIDE/CLIDINIUM BROMIDE- CHLORDIAZEPOXIDE
HYDROCHLORIDE AND CLIDINIUM BROMIDE CAPSULE
A-S MEDICATION SOLUTIONS
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this labeling has not been_
_approved by FDA. For further information about unapproved drugs,
click here._
----------
CHLORDIAZEPOXIDE HYDROCHLORIDE/CLIDINIUM BROMIDE CAPSULES
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS
CONCOMITANT USE OF BENZODIAZEPINES AND OPIOIDS MAY RESULT IN PROFOUND
SEDATION,
RESPIRATORY DEPRESSION, COMA, AND DEATH (SEE WARNINGS AND
PRECAUTIONS).
•
•
•
DESCRIPTION
Chlordiazepoxide Hydrochloride/Clidinium Bromide combines in a single
capsule formulation the
antianxiety action of chlordiazepoxide hydrochloride and the
anticholinergic/spasmolytic effects of
clidinium bromide.
Each Chlordiazepoxide Hydrochloride/Clidinium Bromide capsule contains
active ingredients 5 mg
chlordiazepoxide hydrochloride and 2.5 mg clidinium bromide. Each
capsule also contains inactive
ingredients lactose monohydrate, pregelatinized starch, talc. Gelatin
capsule shells may contain titanium
dioxide with the following dye systems: D&C Yellow #10, FD&C Green #3
and gelatin.
Chlordiazepoxide hydrochloride is a versatile, therapeutic agent of
proven value for the relief of
anxiety and tension. It is indicated when anxiety, tension or
apprehension are significant components of
the clinical profile. It is among the safer of the effective
psychopharmacologic compounds.
Chlordiazepoxide hydrochloride is
7-chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepine 4-oxide
hydrochloride. A colorless, crystalline substance, it is soluble in
water. It is unstable in solution and the
powder must be protected from light. The molecular weight is 336.22.
The structural formula of
chlordiazepoxide hydrochloride is as follows:
Reserve concomitant prescribing of these drugs for use in patients for
whom alternative
treatment options are inadequate.
Limit dosages and durations to the minimum required.
Follow patients for 
                                
                                Lesen Sie das vollständige Dokument
                                
                            

Suchen Sie nach Benachrichtigungen zu diesem Produkt